A closer look at military testosterone screening, clinical diagnosis and TRT evidence following TODAY’s November 3 men’s-health segment.
On November 3, 2026, TODAY published a men’s-health segment featuring board-certified surgeon Dr. Cedrek McFadden on separating evidence from misinformation. Testosterone therapy and cold plunges were among the topics discussed.
For active personnel and veterans evaluating testosterone replacement therapy, or TRT, the segment provides a timely starting point. The central question is how to distinguish a screening result from a medical diagnosis and a treatment claim from evidence of benefit.
The military connection comes from a separate policy development. According to The War Horse, September Pentagon guidance called for annual low-testosterone screening of male service members aged 30 and older. Younger service members could request screening. That policy is relevant context, not evidence that TODAY’s segment addressed military screening rules.
The practical issue is what happens after a result falls below a laboratory cutoff. Screening identifies a result that may deserve further evaluation. Clinical guidance then brings symptoms and confirmation into the decision. Those are different functions, even when public discussion treats them as interchangeable.
For veterans, the distinction matters without implying that the Pentagon policy applies to veteran healthcare. A military screening initiative does not by itself establish a screening requirement for former service members. Its relevance is the broader question of how testosterone findings should inform care after service.
BattleVet connects physical performance with long-term health rather than treating them as separate subjects. That perspective makes the relationship between hormone treatment and military readiness worth examining carefully. A policy that expands testing and evidence that supports treatment answer different questions.
A JAMA research letter published October 15, 2026, estimated how many active-duty male U.S. Army personnel aged 19 to 39 might fall below two commonly used testosterone cutoffs.
According to reporting on the study, the researchers’ weighted estimates were:
These figures describe estimates for readings below specified thresholds. The difference between them shows why the cutoff must remain attached to the percentage whenever the findings are reported. Quoting a percentage without its threshold removes information needed to understand the result.
The estimates came from 479 male participants with one testosterone measurement per participant. The study did not use repeat testing to establish hypogonadism or determine who needed TRT. Its population estimates therefore should not be described as counts of diagnosed hormone disorders or treatment candidates.
The TODAY evidence has a separate boundary. The segment listing identifies its guest and subjects but does not provide a transcript or detailed TRT recommendations. It also does not substantiate particular benefits or risks of cold plunging. The segment is the news peg for this discussion, while clinical guidance and the military study provide the basis for evaluating screening claims.
Keeping those boundaries in one place makes the useful conclusion clearer: the Army figures describe the scale of a screening question. They do not resolve the clinical decisions that follow it.
The Endocrine Society’s guidance, as summarized in Men’s Fitness coverage, calls for compatible symptoms or signs alongside unequivocally and consistently low testosterone. This makes clinical evaluation central to diagnosis rather than treating the laboratory threshold as the entire decision.
The European Association of Urology likewise recommends morning, fasting testing and repeat measurement before treatment when an initial result is low. These recommendations reinforce a confirmation-based approach. They do not turn an expanded screening program into an automatic route to hormone therapy.
For readers assessing a TRT claim, the useful distinction is whether it describes screening or a completed clinical evaluation. A claim about a low reading should remain a claim about that reading. A claim about diagnosed deficiency needs to reflect the symptoms and confirmation required by the cited guidance.
This is also why the timing and conditions of testosterone testing belong in the discussion. Testing conditions are part of interpreting a result, not an optional detail added after a treatment decision has already been made.
Reporting on the Army study notes that testosterone concentrations can vary with age, time of day, obesity, illness and physical stress. That context helps explain why the circumstances surrounding a blood draw matter to clinical interpretation.
The War Horse reports that Defense Health Agency guidance calls for a second confirmatory test after a low result. It also says men recently exposed to exertion, stress or sleep loss during training should wait at least 30 days before a blood draw.
That waiting period is a military-policy detail. It should not be converted into a universal testing rule for veterans or other readers. Personal decisions about testing conditions and timing belong with a qualified clinician who can apply the relevant guidance to the individual situation.
The practical discussion supported by these sources covers symptoms, repeat testing and possible influences on the result. For active personnel, that includes the training context recognized in military guidance. For veterans, the appropriate evaluation remains an individual healthcare question rather than an extension of a service screening policy.
Endocrinologist Darren Katz told New Scientist that treatment can help men with genuine, symptomatic deficiency. He also said current evidence is insufficient to show that TRT improves military readiness, operational performance or fighting capacity.
Those statements address different claims. Treating a diagnosed condition is a medical objective. Promising a general improvement in military performance is a broader assertion that requires evidence for that outcome.
The distinction matters when testosterone discussions move between health and performance without acknowledging the change. Evidence supporting care for symptomatic deficiency should not be carried over into an unsupported promise about readiness. Likewise, the existence of a screening policy does not validate a performance claim.
For readers considering their own health concerns, this supports a clinician-led discussion about the reason for evaluation and the intended purpose of any treatment. It does not support choosing TRT because a headline reports a large screening percentage or because a performance benefit sounds plausible.
The same approach is relevant to evaluating testosterone concerns as veterans age. The useful question is whether a claim addresses the person’s clinical concern with appropriate evidence. A broad statement about male performance is not a substitute for that assessment.
NBC’s accompanying recovery story quoted McFadden on hydration, sleep, refueling and lower-intensity movement. Those subjects belong to the recovery discussion described in that coverage. They should remain distinct from the evidence used to diagnose testosterone deficiency or decide on TRT.
A recovery recommendation and a hormone-treatment recommendation require different support. Mentioning both within men’s-health coverage does not make them interchangeable. Nor does it establish that the recovery practices discussed raise testosterone or replace evaluation for a suspected hormone condition.
For active personnel and veterans, the useful editorial approach is to keep each claim attached to its actual purpose. A statement about recovery should identify a recovery outcome. A statement about TRT should identify the condition being treated and the outcome supported by the evidence.
This avoids turning a broad health segment into a single package of implied benefits. The available coverage supports discussing recovery practices alongside hormone health. It does not support assuming that every topic in the segment works through the same mechanism or belongs in the same treatment plan.
The next research question extends beyond how many readings fall below a cutoff. It concerns how screening findings connect with confirmed diagnoses and decisions that improve health.
For veteran healthcare, useful future work would also examine how lessons from active-duty screening should apply after service. That would require attention to the population being studied and the outcomes being measured rather than assuming that a military policy settles both questions.
As testosterone screening develops, will future research show which evaluation and treatment decisions improve veterans’ health and long-term capability?
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
A look at MHS's CARE-SALTOS update, its long-term research goals, and what the reported VA collaboration means for current care decisions.
A 14-study review highlights fatigue and distress in military drone crews, with implications for sleep, schedules and occupational-health support.
VA highlights links between blast exposure and later diagnoses. Review the findings, evidence limits and implications for veteran health follow-up.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet